Analysis of the cost-effectiveness of proton beam therapy for unresectable pancreatic cancer in Japan.
chemoradiotherapy
cost-effectiveness
incremental cost-effectiveness ratio
locally advanced pancreatic cancer
particle radiotherapy
proton beam therapy
quality-adjusted life year
radiotherapy
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
28
08
2023
received:
21
03
2023
accepted:
22
09
2023
medline:
27
11
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
ppublish
Résumé
Proton beam therapy (PBT) has recently been included in Japan's social health insurance benefits package. This study aimed to determine the cost-effectiveness of PBT for unresectable, locally advanced pancreatic cancer (LAPC) as a replacement for conventional photon radiotherapy (RT). We estimated the incremental cost-effectiveness ratio (ICER) of PBT as a replacement for three-dimensional conformal RT (3DCRT), a conventional photon RT, using clinical evidence in the literature and expense complemented by expert opinions. We used a decision tree and an economic and Markov model to illustrate the disease courses followed by LAPC patients. Effectiveness was estimated as quality-adjusted life years (QALY) using utility weights for the health state. Social insurance fees were calculated as the costs. The stability of the ICER against the assumptions made was appraised using sensitivity analyses. The effectiveness of PBT and 3DCRT was 1.67610615 and 0.97181271 QALY, respectively. The ICER was estimated to be ¥5,376,915 (US$46,756) per QALY. According to the suggested threshold for anti-cancer therapy from the Japanese authority of ¥7,500,000 (US$65,217) per QALY gain, such a replacement would be considered cost-effective. The one-way and probabilistic sensitivity analyses demonstrated stability of the base-case ICER. PBT, as a replacement for conventional photon radiotherapy, is cost-effective and justifiable as an efficient use of finite healthcare resources. Making it a standard treatment option and available to every patient in Japan is socially acceptable from the perspective of health economics.
Sections du résumé
BACKGROUND
BACKGROUND
Proton beam therapy (PBT) has recently been included in Japan's social health insurance benefits package. This study aimed to determine the cost-effectiveness of PBT for unresectable, locally advanced pancreatic cancer (LAPC) as a replacement for conventional photon radiotherapy (RT).
METHODS
METHODS
We estimated the incremental cost-effectiveness ratio (ICER) of PBT as a replacement for three-dimensional conformal RT (3DCRT), a conventional photon RT, using clinical evidence in the literature and expense complemented by expert opinions. We used a decision tree and an economic and Markov model to illustrate the disease courses followed by LAPC patients. Effectiveness was estimated as quality-adjusted life years (QALY) using utility weights for the health state. Social insurance fees were calculated as the costs. The stability of the ICER against the assumptions made was appraised using sensitivity analyses.
RESULTS
RESULTS
The effectiveness of PBT and 3DCRT was 1.67610615 and 0.97181271 QALY, respectively. The ICER was estimated to be ¥5,376,915 (US$46,756) per QALY. According to the suggested threshold for anti-cancer therapy from the Japanese authority of ¥7,500,000 (US$65,217) per QALY gain, such a replacement would be considered cost-effective. The one-way and probabilistic sensitivity analyses demonstrated stability of the base-case ICER.
CONCLUSION
CONCLUSIONS
PBT, as a replacement for conventional photon radiotherapy, is cost-effective and justifiable as an efficient use of finite healthcare resources. Making it a standard treatment option and available to every patient in Japan is socially acceptable from the perspective of health economics.
Identifiants
pubmed: 37795771
doi: 10.1002/cam4.6611
pmc: PMC10652344
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20450-20458Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 19H03596
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Anticancer Res. 2021 Jul;41(7):3589-3595
pubmed: 34230155
Int J Clin Oncol. 2021 May;26(5):941-950
pubmed: 33483857
Radiother Oncol. 2017 Jun;123(3):438-445
pubmed: 28464997
Ann Surg Oncol. 2018 Apr;25(4):1026-1033
pubmed: 29327180
Anticancer Res. 2020 Jan;40(1):465-472
pubmed: 31892602
Health Econ. 2010 Apr;19(4):422-37
pubmed: 19382128
Radiat Oncol. 2019 Feb 7;14(1):30
pubmed: 30732657
Radiother Oncol. 2019 May;134:67-73
pubmed: 31005226
Front Oncol. 2015 Jul 06;5:145
pubmed: 26217585
Int J Gastrointest Cancer. 2001;30(3):123-32
pubmed: 12540024
Am J Clin Oncol. 2019 Jan;42(1):46-55
pubmed: 29965809
Radiat Oncol. 2019 Jun 6;14(1):95
pubmed: 31171025
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1212-1221
pubmed: 29907490
Clin Transl Radiat Oncol. 2019 Oct 31;20:19-26
pubmed: 31754652
Cancer Commun (Lond). 2018 Jun 4;38(1):32
pubmed: 29866170
J Palliat Med. 2021 Sep;24(9):1284-1290
pubmed: 33470878
JAMA. 2021 Sep 7;326(9):851-862
pubmed: 34547082
Cancer Treat Rev. 2020 Jun;86:102016
pubmed: 32247999
World J Gastrointest Oncol. 2015 Sep 15;7(9):141-7
pubmed: 26380057
Cancer. 2016 May 15;122(10):1483-501
pubmed: 26828647
Cancer Chemother Pharmacol. 2009 Jan;63(2):313-9
pubmed: 18398614
Radiother Oncol. 2016 Jul;120(1):140-4
pubmed: 27178145
J Pharm Health Care Sci. 2021 Aug 2;7(1):27
pubmed: 34334136
Surg Oncol. 2021 Jun;37:101542
pubmed: 33740629
Pancreas. 2020 Mar;49(3):326-335
pubmed: 32132516
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancers (Basel). 2021 Jun 04;13(11):
pubmed: 34199796
Jpn J Clin Oncol. 2021 Feb 8;51(2):235-243
pubmed: 33164066
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818783879
pubmed: 29962281
Radiother Oncol. 2019 Jul;136:37-43
pubmed: 31015127
Radiother Oncol. 2018 Nov;129(2):333-339
pubmed: 30224179
Anticancer Res. 2018 Nov;38(11):6537-6542
pubmed: 30396983
Sci Rep. 2020 Dec 10;10(1):21712
pubmed: 33303947
Nagoya J Med Sci. 2019 May;81(2):233-239
pubmed: 31239592
Cancer Med. 2023 Oct;12(20):20450-20458
pubmed: 37795771
Jpn J Radiol. 2018 Jul;36(7):456-461
pubmed: 29748836
Pancreatology. 2020 Apr;20(3):470-476
pubmed: 32033896
J Gastrointest Oncol. 2020 Feb;11(1):166-175
pubmed: 32175120
Med Phys. 2014 Aug;41(8):081711
pubmed: 25086521